Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies

NCT02966171 is registered in ClinicalTrials.gov with Hutchison Medipharma Limited as lead sponsor.

NCT NCT02966171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02966171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies
Lead sponsor
Hutchison Medipharma Limited
Phase
Phase 1
Overall status
Terminated
Start date
January 31, 2017
Completion date
August 23, 2018
Enrollment
14 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor